Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Classifications
Explore trials based on treatment classification/type.
Targets
Explore trials based on treatment targets.
MSK Service
Filter trials based on MSK Service
Accepting patients
BMS-986453
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- GPRC5D
- Phase 1
- Myeloma Service
Accepting patients
RedirecTT-1
A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- GPRC5D
- Phase 1/2
- Myeloma Service
- 23-259
Accepting patients
Investigational Cord Blood Units
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
Learn more- Allogeneic Stem Cell Transplant
- Cord Blood
- Phase 2
- Transplant Service
Accepting patients
Cemsidomide (CFT7455)
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Learn more- IKZF1/3
- Phase 1/2
- Myeloma Service
- 21-301
Accepting patients
JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Learn more- BCMA
- GPRC5D
- Tri-specific Antibody
- Phase 1
- Myeloma Service